Pirarubicin combined with TLR3 or TLR4 agonists enhances anti-tumor efficiency
Our results provide new ideas for the combination strategy of THP with TLR agonists which improves prognosis of breast cancer.
Authors
- Naipeng Cui (ORCID: https://orcid.org/0000-0001-7353-9443)
- Decheng Feng (ORCID: https://orcid.org/0000-0002-1664-4156)
- Yanqiu He
- Yan Qin
- Yaqiong Wang (ORCID: https://orcid.org/0000-0003-3336-2254)
- Jinghua Li (ORCID: https://orcid.org/0000-0003-0533-9890)
- Tong Bao (ORCID: https://orcid.org/0009-0009-9205-0948)
- Ruobing Zhang (ORCID: https://orcid.org/0000-0002-4682-2961)
- Tingting Wang (ORCID: https://orcid.org/0000-0003-1731-3460)
- Jianhong Shi (ORCID: https://orcid.org/0000-0003-2232-1000)
- Chenghan Su
Institutions
- Affiliated Hospital of Hebei University (CN)
- Hebei University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- International Immunopharmacology
- Published
- 2024-09-05
- DOI
- https://doi.org/10.1016/j.intimp.2024.113068
- Citations
- 2
- Primary Topic
- Cancer therapeutics and mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.47
Funders
- National Natural Science Foundation of China